Weight-Loss drug showdown: tirzepatide takes on semaglutide in major trial
NCT ID NCT05822830
First seen Jan 09, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This completed phase 3b study tested whether tirzepatide is better than semaglutide for weight loss in 751 adults with obesity or overweight and related health problems like high blood pressure. Participants received injections of one drug or the other for about 74 weeks. The main goal was to see how much body weight they lost and how many achieved significant weight reduction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, 73069, United States
-
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098, United States
-
Biopharma Informatic, LLC
Houston, Texas, 77043, United States
-
Cahaba Research
Birmingham, Alabama, 35242, United States
-
Cahaba Research - Pelham
Pelham, Alabama, 35124, United States
-
Dallas Diabetes Research Center
Dallas, Texas, 75230, United States
-
Encompass Clinical Research
Spring Valley, California, 91978, United States
-
ForCare Clinical Research
Tampa, Florida, 33613-1244, United States
-
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, 50265, United States
-
L-MARC Research Center
Louisville, Kentucky, 40213, United States
-
Lillestol Research
Fargo, North Dakota, 58104, United States
-
New Horizon Research Center
Miami, Florida, 33165, United States
-
North Texas Endocrine Center
Dallas, Texas, 75231, United States
-
Palm Research Center Sunset
Las Vegas, Nevada, 89148, United States
-
Palm Research Center Tenaya
Las Vegas, Nevada, 89128, United States
-
PharmQuest
Greensboro, North Carolina, 27408, United States
-
Pinnacle Clinical Research
San Antonio, Texas, 78229, United States
-
PlanIt Research, PLLC
Houston, Texas, 77079, United States
-
Prime Health and Wellness/SKYCRNG
Fayette, Mississippi, 39069, United States
-
Puerto Rico Medical Research
Ponce, 00717, Puerto Rico
-
Rocky Mountain Clinical Research
Idaho Falls, Idaho, 83404, United States
-
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, 30291, United States
-
Southern California Dermatology, Inc.
Santa Ana, California, 92701, United States
-
Southern Endocrinology Associates
Mesquite, Texas, 75149, United States
-
StudyMetrix Research
City of Saint Peters, Missouri, 63303, United States
-
The University of Texas Health Science Center at Houston
Bellaire, Texas, 77401, United States
-
Tribe Clinical Research, LLC
Greenville, South Carolina, 29607, United States
-
University Clinical Investigators, Inc.
Tustin, California, 92780, United States
-
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida, 33009, United States
-
WR-Clinsearch, LLC
Chattanooga, Tennessee, 37421, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States
-
Wellness clinical Research Vega Baja
Vega Baja, 00694, Puerto Rico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirzepatide and semaglutide (injectable drugs)
What this could lead to
If tirzepatide proves more effective than semaglutide, it could offer a new, more powerful option for weight loss in people with obesity or overweight.
What could go wrong
This is a completed phase 3 trial, but results may not apply to everyone, and both drugs can cause side effects like nausea or vomiting. Long-term safety and effectiveness beyond the study period are not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.